
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>pmid: 17949897
NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations.
Neoplasms, Animals, Antibodies, Monoclonal, Humans, Neural Cell Adhesion Molecules
Neoplasms, Animals, Antibodies, Monoclonal, Humans, Neural Cell Adhesion Molecules
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 80 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
